

# 50<sup>th</sup> General Assembly of ERIC Members

Wednesday 9<sup>th</sup> June, 2021

# ERIC Information

- **Non-profit organization** according to German law  
Klinik I für Innere Medizin, Universitätsklinikum Köln  
Kerpener Straße 62, 50937, Köln
- Established on 31<sup>st</sup> January 2006
- Executive office:  
Hematology Department, Hospital Sant Pau,  
Mas Casanovas 90, 08041, **Barcelona**, Spain
- **PIC** Number: 930535939

WP7 - European Leukemia Net




Scientific WG - EHA




# ERIC Membership

- **1645 Members**
- **Distributed amongst 85 countries / 700 different institutions**



# ERIC Membership



# TP53 Network

- ERIC promotes and supports, through education, the:
  - Importance of testing **for TP53 aberrations all cases needing therapy, before first and later lines of treatment**
  - Adoption of appropriate diagnostic techniques to ensure reliable and comparable results  
→ **Certification of laboratories**
- The countries in green have at least 1 certified centre
- Besides Europe, ERIC also has certified centres in Australia, Brazil, Canada, China, India, Palestine and Qatar



**215**  
Certified  
Centres from  
37 countries




**11**  
Reference  
Centres



**3**  
Certifying  
Centers



**10**  
Certification Rounds  
completed



# IGHV Network

- ERIC promotes and supports, through education, the:
  - Importance of **immunogenetic analysis** across the medical community before using CIT
  - Adoption of appropriate diagnostic techniques to ensure reliable and comparable results  
→ **Certification of laboratories**
- The countries in blue have at least 1 certified centre
- Besides Europe, ERIC also has certified centres in Argentina, Australia, Canada, South Africa, Taiwan, and USA



**116**  
Certified  
Centres from  
32 countries




**7**  
Reference  
Centres



**2**  
Certifying  
Centers



**5**  
Certification Rounds  
completed



## GenQA and UK NEQAS

GenQA and UK NEQAS LI are pleased to announce that they will be working together with the ERIC TP53 and IG networks to assure the quality of TP53 and IG testing in patients with CLL.

**ERIC will continue to work with laboratories to achieve accuracy of testing through their initial certification** process whilst GenQA and UK NEQAS LI will assure the maintenance of competency among previously certified labs by providing an external quality assessment scheme (EQA). Both the certification and the EQA procedures will follow the same assessment process adhering to ERIC recommendations for analysis and interpretation of TP53 and IG testing.

**These pilot-EQAs are aimed at laboratories that are ERIC certified for TP53 and/or IGH testing** so in case you are not yet certified, please refer to [www.ericll.org/diagnostics](http://www.ericll.org/diagnostics) to learn more on how to participate in a round to obtain the initial certification. Prior participation in ERIC certification enables laboratories that have recently introduced TP53 or IG analyses, or those that have recently introduced new technologies, to benefit from the advice and reassurance on the accuracy of testing that the ERIC network provides before participation in EQA.

# New ERIC Publications

- Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia. *Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, Morales Moshiahshvili M, Ziv-Baran T, Shorer Y, Scarfo L, Joffe E, Perry C, Ghia P.* Blood. 2021 Apr 16;blood.2021011568.
- Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study. *Sutton LA, Ljungström V, Enjuanes A, Cortese D, Skaftason A, Tausch E, Stano Kozubik K, Nadeu F, Armand M, Malcikova J, Pandzic T, Forster J, Davis Z, Oscier D, Rossi D, Ghia P, Strefford JC.*

**“Overall, the current study highlights once more the extraordinary contributions ERIC makes to the standardization of key laboratory data in CLL including IGHV sequencing, diagnostic flow cytometry, and the detection of minimal residual disease.”**

Greece. *Karamanidou C, Xochelli A, Papaioannou M, Moysiadis T, Scarfo L, Mattsson M, Stavroyianni N, Rosenquist R, Ghia P, Stamatopoulos K.* Hemasphere. 2021 Feb 23;5(3):e546.

- EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia. *Eichhorst B, Ghia P.* Hemasphere. 2020 Dec 29;5(1):e520.
- Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. *Cuneo A, Mato AR, Rigolin GM, Piciocchi A, Gentile M, Laurenti L, Allan JN, Pagel JM, Brander DM, Hill BT, Winter A, Lamanna N, Tam CS, Jacobs R, Lansigan F, Barr PM, Shadman M, Skarbnik AP, Pu JJ, Sehgal AR, Schuster SJ, Shah NN, Ujjani CS, Roeker L, Orlandi EM, Billio A, Trentin L, Spacek M, Marchetti M, Tedeschi A, Ilariucci F, Gaidano G, Doubek M, Farina L, Molica S, Di Raimondo F, Coscia M, Mauro FR, de la Serna J, Medina Perez A, Ferrarini I, Cimino G, Cavallari M, Cucci R, Vignetti M, Foà R, Ghia P; GIMEMA, European Research Initiative (ERIC) on CLL, US study group.* Cancer Med. 2020 Nov;9(22):8468-8479.
- Challenges and Solutions for Collecting and Analyzing Real World Data: The Eric CLL Database as an Illustrative Example. *Chatzidimitriou A, Minga E, Chatzikonstantinou T, Moreno C, Stamatopoulos K, Ghia P.* Hemasphere. 2020 Sep 30;4(5):e425.



# 2020 ERIC Workshops

## **ERIC WORKSHOP AT THE EHA-ISHBT HEMATOLOGY TUTORIAL 2020**

- 27 FEBRUARY, 2020 (CHANDIGARH, INDIA)

## **ERIC INTERNATIONAL MEETING**

- 01-03 OCTOBER, 2020 (VIRTUAL)

## **ERIC MRD WORKSHOP TAIWAN**

- 7-8 NOVEMBER, 2020 (TAIWAN, VIRTUAL)

## **SEMINAR SERIES: BIOMARKERS FOR DECISION-MAKING IN CLL**

- SEPTEMBER, 2020 (VIRTUAL)

## **DIAGNOSTIC SUMMIT: OPTIMISING THE PRECISION MANAGEMENT OF PATIENTS WITH CANCER**

- OCTOBER, 2020 (VIRTUAL)

# 2021 ERIC Workshops

## **50<sup>TH</sup> GENERAL ASSEMBLY**

- 9 JUNE, 2021 (EHA, VIRTUAL)

## **ERIC WORKSHOPS ON MOLECULAR BIOMARKERS IN CLL (VIRTUAL)**

- 29-30 SEPTEMBER – 1 OCTOBER, 2021 (MEDITERRANEAN/GULF REGION)
- 12-14 OCTOBER, 2021 (BALTICS/SCANDINAVIA)
- 9-11 NOVEMBER, 2021 (CENTRAL EASTERN EUROPE)
- 23-25 NOVEMBER, 2021 (WESTERN EUROPE)

## **ERIC MRD WORKSHOP JAPAN**

- 1-2 NOVEMBER, 2021 (JAPAN, VIRTUAL)

# 50<sup>th</sup> General Assembly of ERIC Members

## - Agenda -

- 17:00 - 17:05** Welcome and Introduction – *P. Ghia*
- 17:05 - 17:15** New Project. Vaccines in CLL – *Y. Herishanu*
- 17:15 - 17:25** New project. Database of *TP53* mutations in CLL – *J. Malcikova*
- 17:25 - 17:30** Update. Minor *TP53* variants in CLL – *S. Pavlova*
- 17:30 - 17:40** Update. COVID-19 – *T. Chatzikonstantinou*
- 17:40 - 17:50** Update. Mutations in CLL – *R. Rosenquist*
- 17:50 - 18:00** Update. Other malignancies in CLL – *K. Stamatopoulos*

**THANK YOU VERY MUCH  
FOR YOUR ATTENTION**



**[www.ericll.org](http://www.ericll.org)**